For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Adalank?
Adalank is a synthetic peptide analog related to the Selank/Semax family of Russian nootropic peptides. It belongs to the class of tuftsin-derived peptides and shares pharmacological properties with Selank, combining anxiolytic, nootropic, and immunomodulatory effects in a single compound.
Mechanism of Action
Adalank exerts its effects through interaction with the enkephalin system and modulation of BDNF expression. It appears to regulate the balance between GABAergic inhibition and glutamatergic excitation in key limbic structures, producing anxiolytic effects without sedation — a profile distinct from benzodiazepines. It also modulates IL-6 and other cytokines, contributing to its anti-inflammatory and immunoregulatory properties.
Research Applications
Research in Russia has examined Adalank for generalized anxiety, mild depression with anxiety features, chronic stress, and cognitive performance under stress conditions. Studies report reduction in anxiety scores, improved working memory, and normalization of stress-related hormonal responses. Like Selank, it is primarily administered intranasally in research settings.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Uchakina, O.N., Uchakin, P.N., Miasoedov, N.F., et al., 2008, Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova - Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Inozemtsev, A.N., Bokieva, S.B., Karpenko, M.N., et al., 2019, Bulletin of Experimental Biology and Medicine - Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Kasian, A., Kirbaeva, N., Volodina, M., et al., 2017, Behavioural Neurology - GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Filippenkov, I.B., Stavchansky, V.V., Denisova, A.E., et al., 2017, Frontiers in Pharmacology - The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action
Sebentsova, E.A., Denisenko, A.V., Levitskaya, N.G., et al., 2013, Immunopharmacology and Immunotoxicology - Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank
Levitskaya, N.G., Sebentsova, E.A., Manchenko, D.M., et al., 2011, Regulatory Peptides - Immunomodulatory effects of selank in patients with anxiety-asthenic disorders
Kolomin, T.A., Agapova, T.Y., Agniullin, Y.V., et al., 2013, Immunopathology, Allergology, Infectology - Optimization of the treatment of anxiety disorders with selank
Kolik, L.G., Nadorova, A.V., Kozlovskaya, M.M., et al., 2015, Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova